沃森生物(300142.SZ):擬調整“玉溪沃森疫苗產業園三期工程項目”達到預定可使用狀態時間
格隆匯 3 月 26日丨沃森生物(300142.SZ)公佈,玉溪沃森疫苗產業園三期工程項目主要實施Hib疫苗和系列流腦疫苗原液生產車間的易地新建,實施系列肺炎疫苗的產業化車間的新建,建設動物房、科研質檢樓、發貨中心、疫苗生產標準廠房、綜合樓等配套設施。項目總投資64734.30萬元,現已完成投資64449.29萬元,完成投資進度的99.56%。
該項目目前除分包裝車間尚未完成整體調試外,其它廠房設施均已投入運營使用。隨着近年來行業監管要求不斷提升,同時,公司多產品產能不斷釋放,並推進國際市場佈局,為滿足更高標準、更長遠的項目需求,該項目分包裝車間需進行調試優化。由於疫苗行業產業化具有特殊性,需待車間整體進行聯動調試並完成調試驗證後,才能申請進行GMP認證檢查。根據項目實施進展,經公司認真研究,本着謹慎使用募集資金的原則,擬將項目達到預定可使用狀態的時間調整為2021年12月31日。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.